Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 379-387

  Yang, Hailin ^a   Kim, Sung Kwon ^b   Kim, Mikyung ^a   Reche, Pedro A ^a   Morehead, Tiara J ^c   Damon, Inger K ^c   Welsh, Raymond M ^b   Reinherz, Ellis L ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANILINOQUINAZOLINE DERIVATIVE; ANTIVIRUS AGENT; CANERTINIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR; MONOCLONAL ANTIBODY; SMALLPOX GROWTH FACTOR; UNCLASSIFIED DRUG; CBL PROTEIN; CBL PROTEIN, MOUSE; DNA; GROWTH PROMOTOR; MORPHOLINE DERIVATIVE; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; ENZYME SUBSTRATE; HELA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERNALIZATION; MALE; MOLECULAR MODEL; MONKEY; MOUSE; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SMALLPOX VIRUS; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; CERCOPITHECUS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PATHOLOGY; PNEUMONIA; PROTEIN TRANSPORT; SMALLPOX; VACCINIA; VERO CELL; VIROLOGY;

ANIMALS; CERCOPITHECUS AETHIOPS; DNA; GROWTH SUBSTANCES; HELA CELLS; HUMANS; MALE; MICE; MORPHOLINES; PNEUMONIA; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SMALLPOX; T-LYMPHOCYTES; UBIQUITIN-PROTEIN LIGASES; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS; VERO CELLS; VIRAL PROTEINS;

EID: 14944382916     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200523220     Document Type: Article

References (32)

1. Balfour, H.H. 1999. Antiviral drugs. N. Engl. J. Med. 340:1255-1268.
2. Dolin, R. 2001. Antiviral chemotherapy, excluding antiretroviral drugs. In Principles of Internal Medicine. 15th edition. E. Braunwald et al., editors. McGraw-Hill. New York, New York, USA. 1092-1100.
3. Fauci, A.S., and Lane, H.C. 2001. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In Principles of Internal Medicine. 15th edition. E. Braunwald et al., editors. McGraw-Hill. New York, New York, USA. 1852-1913.
4. Fenner, F., Wittek, R., and Dumbell, K.R. 1988. The orthopoxviruses. Academic Press. San Diego, California, USA. 432 pp.
5. Henderson, D.A., et al. 1999. Smallpox as a biological weapon: Medical and public health management. JAMA. 281:2127-2137.
6. Buller, R.M., Chakrabarti, S., Cooper, J.A., Twardzik, D.R., and Moss, B. 1988. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 62:866-874.
7. Opgenorth, A., Nation, N., Graham, K., and McFadden, G. 1993. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology. 192:701-709.
8. Kim, M., et al. 2004. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279:25838-25848.
9. Yarden, Y., and Sliwkowski, M.X. 2001. Untangling the erbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.
10. Cockerill, G.S., and Lackey, K.E. 2002. Small molecule inhibitors of the class I receptor tyrosine kinase family. Curr. Top. Med. Chem. 2:1001-1010.
11. Wakeling, A.E. 2002. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2:382-387.
12. Stamos, J., Sliwkowski, M.X., and Eigenbrot, C. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:46265-46272.
13. Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, W.L., and Fry, D.W. 2002. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. Oncol. 29:11-21.
14. Fry, D.W., et al. 1998. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 95:12022-12027.
15. Soubeyran, P., Kowanetz, K., Symkiewicz, I., Langdon, W.Y., and Dikic, I. 2002. Cb1-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 416:183-187.
16. Xu, W., et al. 2001. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 276:3702-3708.
17. Citri, A., et al. 2002. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21:2407-2417.
18. Lynch, D.K., et al. 2003. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J. Biol. Chem. 278:21805-21813.
19. Chen, H.D., et al. 2001. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat. Immunol. 2:1067-1076.
20. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.
21. Seet, B.T., et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
22. Tzahar, E., et al. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17:5948-5963.
23. Fry, D.W., et al. 1994. Specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1093-1095.
24. Levitzki, A., and Gazit, A. 1995. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1782-1788.
25. Menzo, S., et al. 1993. Transactivation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology. 196:878-882.
26. Miller, W.E., Earp, H.S., and Raab-Traub, N. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398.
27. Adelsman, M.A., Huntley, B.K., and Maihle, N.J. 1996. Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions. J. Virol. 70:2533-2544.
28. Strong, J.E., Tang, D., and Lee, P.W.K. 1993. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology. 197:405-411.
29. Wang, X., Huong, S.-M., Chiu, M.L., Raab-Traub, N., and Huang, E.-S. 2003. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature. 424:456-461.
30. Yoo, J.-Y., and Desiderio, S. 2003. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc. Natl. Acad. Sci. U. S. A. 100:1157-1162.
31. Selin, L.K., Varga, S.M., Wong, I.C., and Welsh, R.M. 1998. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188:1705-1715.
32. Earl, P.L., Cooper, N., Wyatt, L.S., Moss, B., and Carroll, M.W. 2004. Preparation of cell cultures and vaccinia virus stocks. In Current Protocols in Molecular Biology. F.M. Ausubel et al., editors. John Wiley & Sons. New York, New York, USA. 16.16.